Deals & Cases

Santhera Enters into Option and Sublicense Agreement with Idorsia

22.11.2018

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare and other diseases with high unmet medical needs. On 20 November 2018, Santhera Pharmaceuticals announced that it had entered into an agreement with Idorsia Ltd (SIX: IDIA) under which Santhera will acquire the option to exclusively in-license, by way of sublicense, the steroid vamorolone in all indications and all countries worldwide except Japan and South Korea. Vamorolone is a highly promising drug candidate for the treatment of patients with Duchenne muscular dystrophy.

Schellenberg Wittmer advised Santhera Pharmaceuticals on this matter.

The team was led by Philipp Groz (IP / Life Sciences) and included Marcel Jakob (Corporate/M&A).

 

Stay up to date!

*Required fields

Newsletters & Newsflashes

Monthly selected key topics from our practice areas, sectors and industries, plus newsflashes on recent developments.

Publications

Monthly email with the latest updates and summaries of the Swiss Federal Supreme Court's case law in arbitration matters.
Regular insights into Swiss and international trends and legal developments in the construction industry.
NEW
Regular insights and updates on key developments in the rapidly changing landscape of Environmental, Social and Corporate Governance disputes.
Concise analysis of key trends in the fast-moving world of corporate governance for board members of Swiss companies.
A regular look from a unique M&A perspective at legal changes, economic developments and societal trends in Switzerland.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.